Relay Therapeutics (RLAY) Net Margin (2021 - 2026)
Relay Therapeutics (RLAY) reported Net Margin of 2441.27% for Q1 2026, down 143780.0% year-over-year from N/an in Q1 2025, and down 211.16% on a QoQ basis from 784.57% in Q4 2025.
Relay Therapeutics (RLAY) has 6 years of Net Margin data on file, last reported at 2441.27% in Q1 2026.
- Quarterly Net Margin fell 143780.0% year-over-year to 2441.27% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2546.45% (up 179482.0% YoY) and the FY2025 annual result came in at 1795.53%, up 157933.0% from the prior year.
- Net Margin slipped to 2441.27% in Q1 2026 per RLAY's latest filing, from 784.57% in the prior quarter.
- Across five years, Net Margin topped out at 8349600.0% in Q4 2023 and bottomed at 82765.55% in Q2 2023.
- The 5-year median for Net Margin is 10301.62% (2025), against an average of 624810.57%.
- Peak annual rise in Net Margin reached 837627154 bps in 2023, while the deepest fall reached 6172281 bps in 2023.
- Tracing RLAY's Net Margin over 5 years: stood at 26671.54% in 2022, then surged by 31405 bps to 8349600.0% in 2023, then slumped by 100 bps to 813.55% in 2024, then gained by 4 bps to 784.57% in 2025, then plunged by 211 bps to 2441.27% in 2026.
- Per Business Quant, the three latest RLAY Net Margin figures stand at 2441.27% (Q1 2026), 784.57% (Q4 2025), and 10301.62% (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.65% |
| 10 | Relay Therapeutics | 2.53 Bn | 2.53 Bn | - | -2,441.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,441.27% |
| Dec 31, 2025 | -784.57% |
| Jun 30, 2025 | -10,301.62% |
| Mar 31, 2025 | -1,003.46% |
| Mar 31, 2024 | -813.55% |
| Dec 31, 2023 | 8,349,600.00% |
| Sep 30, 2023 | -260.82% |
| Jun 30, 2023 | -82,765.55% |
| Mar 31, 2023 | -41,698.67% |
| Dec 31, 2022 | -26,671.54% |
| Sep 30, 2022 | -24,470.64% |
| Jun 30, 2022 | -21,042.74% |
| Mar 31, 2022 | -14,808.11% |
| Dec 31, 2021 | -11,897.00% |
| Sep 30, 2021 | -9,134.08% |
| Jun 30, 2021 | -22,914.69% |
| Mar 31, 2021 | -4,431.09% |